Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy
R De Santis - MAbs, 2020 - Taylor & Francis
Over the past 3 decades, monoclonal antibodies and their related derivatives, including
recently approved antibody-drug conjugates, conquered a central role in cancer therapy …
recently approved antibody-drug conjugates, conquered a central role in cancer therapy …
Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy.
R De Santis - Mabs, 2020 - europepmc.org
Over the past 3 decades, monoclonal antibodies and their related derivatives, including
recently approved antibody-drug conjugates, conquered a central role in cancer therapy …
recently approved antibody-drug conjugates, conquered a central role in cancer therapy …
[PDF][PDF] Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy
R De Santis - 2020 - scienceopen.com
Over the past 3 decades, monoclonal antibodies and their related derivatives, including
recently approved antibody-drug conjugates, conquered a central role in cancer therapy …
recently approved antibody-drug conjugates, conquered a central role in cancer therapy …
Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy
R De Santis - mAbs, 2020 - pubmed.ncbi.nlm.nih.gov
Over the past 3 decades, monoclonal antibodies and their related derivatives, including
recently approved antibody-drug conjugates, conquered a central role in cancer therapy …
recently approved antibody-drug conjugates, conquered a central role in cancer therapy …
[引用][C] Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy
R De Santis - mAbs, 2020 - cir.nii.ac.jp
Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
[HTML][HTML] Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy
R De Santis - mAbs, 2020 - ncbi.nlm.nih.gov
Over the past 3 decades, monoclonal antibodies and their related derivatives, including
recently approved antibody-drug conjugates, conquered a central role in cancer therapy …
recently approved antibody-drug conjugates, conquered a central role in cancer therapy …